A Randomized Study of Sulindac in Oral Premalignant Lesions

NCT00299195 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Leukoplakia, Oral
Benign Neoplasms

Interventions

DRUG: sulindac
DRUG: Placebo

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]